Tectonic Therapeutic, Inc.
$28.76
▼
-0.84%
2026-04-21 09:46:01
tectonictx.com
NGM: TECX
Explore Tectonic Therapeutic, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$554.1 M
Current Price
$28.76
52W High / Low
$36.03 / $14.39
Stock P/E
—
Book Value
$13.41
Dividend Yield
—
ROCE
-33.43%
ROE
-37.82%
Face Value
—
EPS
$-4
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
60
Beta
—
Debt / Equity
0.51
Current Ratio
26.62
Quick Ratio
26.63
Forward P/E
-6.56
Price / Sales
—
Enterprise Value
$324.3 M
EV / EBITDA
-3.92
EV / Revenue
—
Rating
Strong Buy
Target Price
$78.25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Quantum BioPharma Ltd. | $3.12 | — | $25.24 M | — | -300.19% | -3.47% | $52 / $2.85 | $1.81 |
| 2. | AC Immune SA | $2.98 | — | $303.29 M | — | -115.62% | -89.65% | $4 / $1.45 | $0.56 |
| 3. | Silo Pharma, Inc. | $0.67 | — | $8.38 M | — | -61.55% | -74.57% | $1.19 / $0.22 | $0.47 |
| 4. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
| 5. | Agenus Inc. | $4.42 | 1,529.26 | $175.86 M | — | 21.26% | -0.04% | $7.34 / $1.6 | $-7.68 |
| 6. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 7. | VYNE Therapeutics Inc. | $0.63 | — | $20.33 M | — | -107.15% | -66.96% | $1.99 / $0.28 | $0.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -21.52 M | -21.89 M | -22.33 M | -18.3 M | -13.99 M |
| Net Profit | -19.23 M | -19.04 M | -19.98 M | -15.91 M | -12.37 M |
| EPS in Rs | -1.02 | -1.01 | -1.06 | -0.85 | -0.66 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -84.04 M | -58.02 M | -44.65 M | -32.83 M |
| Net Profit | -74.15 M | -57.98 M | -42.82 M | -32.18 M |
| EPS in Rs | -3.95 | -3.09 | -2.28 | -1.71 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 261.04 M | 152.91 M | 39.4 M | 47.21 M |
| Total Liabilities | 9.71 M | 12.13 M | 124.03 M | 92.86 M |
| Equity | 251.33 M | 140.78 M | -84.64 M | -45.65 M |
| Current Assets | 257.36 M | 146.86 M | 30.88 M | 37.04 M |
| Current Liabilities | 9.67 M | 11.61 M | 40.89 M | 7.84 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -60.08 M | -59.08 M | -40.68 M | -27.64 M |
| Investing CF | -0.14 M | -0.16 M | -0.28 M | -2.09 M |
| Financing CF | 173.35 M | 171.71 M | 33.75 M | 37.63 M |
| Free CF | -60.29 M | -59.24 M | -40.96 M | -29.73 M |
| Capex | -0.21 M | -0.16 M | -0.28 M | -2.09 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -35.4% | -33.07% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-06-21 | 1:0.0833333 |